Overview
Arcus Biosciences
?
Terry Rosen
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Biotechnical research, commercial
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Modelled
?
Actual
$258.00 million
Actual
120.51%
$1,150
DEC
?
?
NYSE:RCUS
Contacts
Get in Touch with 7 Principals* and 259 Contacts
-
Terry RosenChairman of the Board and Chief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$258.00 million
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | -$170 | -$306 | $438 |
| Net Investing Cash | -$84 | $194 | -$413 |
| Net Financing Cash | $277 | $33 | $33 |
| Net Change in Cash | $23 | -$79 | $58 |
| Cash at Beginning of Period | $130 | $209 | $151 |
| Cash at End of Period | $153 | $130 | $209 |
| Capital Expenditure | -$6 | -$24 | -$6 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $150 | $127 | $206 |
| Accounts Receivable | $20 | $38 | $39 |
| Inventories | $ | $ | $ |
| Other Current Assets | $846 | $666 | $822 |
| Asset Summary | |||
| Total Current Assets | $1,016 | $831 | $1,067 |
| Tangible Fixed Assets | $47 | $51 | $35 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $1,150 | $1,095 | $1,345 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $18 | $17 | $20 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $208 | $167 | $173 |
| Liability Summary | |||
| Total Current Liabilities | $226 | $184 | $193 |
| Long-Term Debt | $48 | $ | $ |
| Other Long-Term Liabilities | $157 | $142 | $140 |
| Total Liabilities | $665 | $633 | $688 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $1,617 | $1,311 | $1,206 |
| Retained Earnings | -$1,132 | -$849 | -$542 |
| Equity Summary | |||
| Total Equity | $485 | $462 | $657 |
| Shares Outstanding | 92,200,000 | 75,500,000 | 72,900,000 |